RECHERCHE
boerse.de
Europas erstes Finanzportal
Aktien-Ausblick
kostenlos, schon >150.000 Leser
boerse.de-Aktienbrief
kostenlos + unverbindlich
Börsendienste
kostenlos + unverbindlich kennenlernen
Leitfaden für Ihr Vermögen
einzigartiges Börsenwissen kostenlos
INVESTMENT
boerse.de-Gold (TMG0LD)
Responsible Gold!
boerse.de-Fonds - ohne Agio!
boerse.de-Aktienfonds
boerse.de-Weltfonds
boerse.de-Technologiefonds
boerse.de-DividendenfondsNEU
boerse.de-Indizes
BCDI -
Das Original!
BCDI
USA
BCDI Deutschland
myChampionsPREMIUM
ab 500.000 Euro
myChampions100
Aktion: Ab 50.000 Euro
ÜBER UNS
SANTA BARBARA, Calif. –
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan José Chacón-Quirós will participate in the 39th Annual J.P. Morgan Healthcare Conference, which is being held January 11-14, 2021. Mr. Chacón-Quirós is scheduled to speak to conference attendees at 4:30 pm ET on Thursday, January 14, 2021.
A live webcast of the presentation will be available to all interested parties on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. An archived version of the webcast will be available on the same website following the completion of the event.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs’ product and technologies portfolio includes the Divina® 3D Simulation System and other products and services. Please visit our website for additional information at www.establishmentlabs.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005229/en/
boerse.de-Börsenzitat:
Diejenigen, die immer davon reden, dass alle in einem Boot sitzen, sind meistens diejenigen, die sich rudern lassen.
Ich bin damit einverstanden, dass die TM Börsenverlag AG und die Schwestergesellschaft boerse.de Vermögensverwaltung GmbH
mir regelmäßig Informationen zu aktuellen Produkten und Dienstleistungen aus dem Finanzbereich,
sowie den kostenlosen Newsletter boerse.de-Aktien-Ausblick zuschickt. Meine Einwilligung kann ich
jederzeit gegenüber der TM Börsenverlag AG widerrufen.
Unsere Datenschutzerklärung finden Sie hier.